immunology of primary sclerosing cholangitis
play

Immunology of Primary Sclerosing Cholangitis John M. Vierling, M.D., F.A.C.P. Professor of Medicine and Surgery Director, Baylor Liver Health Chief of Hepatology Baylor School of Medicine Director of Advanced Liver Therapies St. Lukes

0 downloads 4 Views 2,02 MB Size Report
  1. Immunology of Primary Sclerosing Cholangitis John M. Vierling, M.D., F.A.C.P. Professor of Medicine and Surgery Director, Baylor Liver Health Chief of Hepatology Baylor School of Medicine Director of Advanced Liver Therapies St. Luke’s Episcopal Hospital Houston, TX

  2. Anatomy of Bile Ducts

  3. Artery Portal Vein Anatomy of Bile Ducts Duct Bile

  4. ERC Pathology Primary Sclerosing Cholangitis

  5. Pathology of Primary Sclerosing Cholangitis Small Ducts Medium Ducts

  6. Pathology of Primary Sclerosing Cholangitis Blood Vessels Pushed Away from Bile Ducts Small Ducts Medium Ducts

  7. Past Antibodies (Vaccinations, Responses to infections) Antigen Response Cell Mediated Killing (Viruses, Tumors, Rejection of transplanted organs Present Antigen Response

  8. Immunology of Primary Sclerosing Cholangitis The Three “Rs” Your immune response has 3 functions: � Recognize � Respond � Remember

  9. Immunology of Primary Sclerosing Cholangitis Your immune response: � Recognize: � Foreign antigens � Avoid self antigens (autoantigens)

  10. Immunology of Primary Sclerosing Cholangitis Your immune response: � Respond: � Innate immune response � Immediate “ready to go” response � Triggered by molecules on bacteria, viruses, tumor cells � Influences adaptive immune responses � Adaptive immune response

  11. Immunology of Primary Sclerosing Cholangitis Your immune response: � Respond: � Adaptive immune response � Small, processed proteins (antigens) � Presentation of antigens by HLA molecules to T cells and B cells � Activation of T and B cells to antigens

  12. Immunology of Primary Sclerosing Cholangitis Your immune response: � Respond: � Important to: � Regulate both magnitude and duration � Shut off response once it has served it purpose

  13. Immunology of Primary Sclerosing Cholangitis Your immune response: � Respond: � Self or autoantigens= autoimmunity � Break in self-tolerance � As if self were foreign

  14. Innate Immune Response Part One Fragments of dead cells Special Proteins Particles: � Attract inflammatory cells � Bacteria � Intensify inflammation � Viruses � Increase destructive � Bacterial DNA adaptive immune response Antibodies bound to proteins

  15. � Cells under stress Recognize and Kill � Infected cells � Tumor cells Innate Immune Response Part Two Natural Killer Cells

  16. Adaptive Immune Response CD4 Th2 CD4 Antigens Th0 B7- CD28 CD4 Antigen Th1 Presenting NK Cell B 7 - C D 2 8 CD8 CD8 CTL

  17. Immunogenetics in PSC II III I Class HLA B C A DP DQ DR CD4 Th2 CD4 Antigens Th0 CD4 Antigen Th1 Presenting NK Cell CD8 CD8 CTL

  18. Immunogenetics in PSC II III I Class HLA B C A DP DQ DR CD4 Susceptibility Th2 CD4 Antigens Th0 CD4 Antigen Th1 Presenting NK Cell CD8 CD8 CTL

  19. Immunogenetics in PSC II III I Class HLA B C A DP DQ DR C’4, 2, C4AQ0, MICA, HSPs, TNF α/β Antigen Antigen

  20. Adaptive Immune Response CD4 Innate Th2 Immune IL-4 Response CD4 Antigens Th0 B7- CD28 IFN γ CD4 Antigen Th1 Presenting NK IL-2 Cell B7-CD28 CD8 CD8 CTL

  21. Adaptive Immune Response IL-4 Antibodies B CD4 B (Autoantibodies) Th2 IL-4 CD4 Antigens Th0 B7- CD28 IFN γ CD4 Antigen Th1 Presenting NK IL-2 Cell IFN γ B MAC 7 - C D 2 8 Cell-Mediated Killing CD8 CD8 CTL

  22. Immunogenetic Associations in PSC II III I Class HLA B C A DP DQ DR Complement, MICA, HSPs, TNF α/β Susceptibility OR • B8-TNFA*2-MICA*008-DRB3*0101-DRB1*0301-DQA1*0501 DQB1*0201 2.69 • DRB3*0101-DRB1*1301-DQA1*0103-DQB1*0603 3.80 • DRB5*0101-DRB1*1501-DQA1*01102-DQB1*0602 1.52 • MICA*008 5.0 Resistance • DRB4*-DRB1*0401-DQA1*0301-DQB1*0302 0.26 • DRB4*-DRB1*0701-DQA1*0201-DQB1*0303 0.15 • MICA*002 0.12 Donaldson PT, Norris S. Autoimmunity 2002; 35: 555-64; Neri, et al: Dig Liver Dis 2003;35: 571-6; Sheth S, et al. Hum Genet 2003; 113: 286-92; ter Borg PC, et al: Neth J Med 2004; 62: 326-31; ERi R, et al: Genes Immun 2004; 5: 444-50; Yang X, et al: J Hepatol 2004; 40: 375-9

  23. Is PSC an Autoimmune Disease? Comparison of Classical Autoimmunity and PSC Classical Autoimmunity PSC • Females more than males No • Afflicts children & adults Yes • HLA susceptibility associations Yes • Autoantigen(s) No • Autoantibodies or cell-mediated reactions to No autoantigens • Associated with other “immune diseases” Yes • Responds to immunosuppression treatment No

  24. Rat Model of Small Bowel Bacterial Overgrowth � Mutanolysin � Palmitate Peptidoglycan-polysaccahride (PG-PS PAMP) • Small Bowel Overgrowth • Genetically susceptible rats Lichtman SN, et al: J Clin Invest 1992; 90: 1313-22

  25. Immune Mechanisms in Sclerosing Cholangitis Spontaneous Sclerosing Cholangitis in Mdr2 -/- Mouse Fickert et al., Gastroenterology 2002; 123: 1238

  26. Immune Mechanisms in Sclerosing Cholangitis Spontaneous Sclerosing Cholangitis in Mdr2 -/- Mouse � Genetic cause of bile leak between bile duct lining cells � Bile triggers innate immune inflammation and adaptive immunity � Innate immune cells produce inflammatory chemicals � These chemicals activate cells to form scar around the bile duct � As the scar thickens, blood vessels pushed away from the bile duct � Shrinkage of the lining cells of the bile duct due to lack of oxygen and nutrition supplied by D Fickert P, et al. Gastroenterology 2004; 127: 261-74.

  27. Immune Reactions in PSC Particles Inflammatory from Molecules Bacteria Innate Immune Signalling E-cadherin CD1d ↑ HSP CD40 ICAM-1 B7 B7 Bile Duct MHC I Diapedesis MHC II CCL28 CCL28 Lining Cell Fas Fas VCAM-1 LFA-3 CD44 Inflammatory Cells Originally Activated in the Gut Adherent TNF α R CCRs IL-6R CXCRs Chemicals Chemicals Growth that that Factors Rolling for Cause Attract Cells Inflammation Inflammatory Producing and Cells Scar to Scarring Cholangiocytes Blood Flow

  28. Possible Sequence of Events in Primary Sclerosing Cholangitis Cytokines, Chemokines, Fibrosing Inflammation Bile Adaptive Immunity Regurgitation + Innate Immunity Abnormal Cholangiocyte Bacterial Functions Molecules Into Portal Vein Displacement Of Arterial Vessels Atrophy of Immune and Other Genetic Ulcerative or Crohn’s Cholangiocytes Susceptibilities Colitis

  29. Immunology of Primary Sclerosing Cholangitis � Fund research! � Without your advocacy, we will remain, in the words of Pogo: “Surrounded by insurmountable opportunities.”

Recommend Documents


primary biliary cholangitis pbc
Primary Biliary Cholangitis (PBC)

Primary Biliary Cholangitis (PBC) Formerly known as primary biliary cirrhosis

michael trauner div of gastroenterology amp hepatology
Michael Trauner Div. of

Session 2: Primary Sclerosing Cholangitis (PSC) Potential trial design and

colons cholangio s and controversies
Colons, Cholangios and Controversies

Colons, Cholangios and Controversies Bilal Bobat Consultant

what s new in hepatology aasld 2016
Whats new in Hepatology AASLD 2016

Whats new in Hepatology AASLD 2016 CWN Spearman C Kassianides Whats new in

diagnosis surveillance and
diagnosis, surveillance, and

HKASLD 27 th Annual Scientific Meeting 2014 Primary Sclerosing Cholangitis

5 23 2015
5/23/2015 Small Glandular

5/23/2015 Small Glandular Proliferative Complex sclerosing lesion Benign

uncertainty
UNCERTAINTY Immunology of Covid-19 Dr

Foresight Dialogues Web Series 2020 UNCERTAINTY Immunology of Covid-19 Dr

immunology and immunotoxicity immunology and
Immunology and Immunotoxicity

Immunology and Immunotoxicity Immunology and Immunotoxicity of Nanomedicines

authorisation of ocaliva for pbc in the eu
Authorisation of Ocaliva for PBC in the

Authorisation of Ocaliva for PBC in the EU EMA stakeholder interaction on the

update on
Update on Immunoglobulin Use for

Update on Immunoglobulin Use for Primary Immunodeficiency Bob Geng, MD

targeting the cause of
Targeting the cause of

Targeting the cause of neurodegenerative and autoimmune diseases January

selecting for immune
Selecting for Immune Competence in

ImmuneDEX: Measuring and Selecting for Immune Competence in Angus Presented

leveraging the natural strengths of humanity and our
Leveraging the natural strengths of

KIADIS PHARMA | COMPANY PRESENTATION | NOVEMBER 2019 EURONEXT: KDS

to fight cancer
TO FIGHT CANCER Company presentation

ACTIVATING THE PATIENTS IMMUNE SYSTEM TO FIGHT CANCER Company presentation

te tekna na cepi s mission and activit vities ies rega
Te Tekna na CEPIs mission and activit

Te Tekna na CEPIs mission and activit vities ies rega garding ding COVI

immunobricks bricks immuno immunobricks immunobricks
Immunobricks bricks Immuno

Immunobricks bricks Immuno Immunobricks Immunobricks toprepare ahi-tech

center for viral pathogenesis research symposium november
Center for Viral Pathogenesis Research

Center for Viral Pathogenesis Research Symposium November 29, 2017 University

s
S ince the beginning of the new

MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering

extending the systems model of platelet homeostasis to
Extending the Systems Model of Platelet

Extending the Systems Model of Platelet Homeostasis to Understand Platelet

ge gene therapy ear arly ly clin clinic ical de develo
Ge Gene Therapy: Ear arly ly Clin

Ge Gene Therapy: Ear arly ly Clin Clinic ical De Develo lopment Ch

pathogens and commensals war and peace at mucosal surface
Pathogens and commensals: War and

Pathogens and commensals: War and Peace at mucosal surface Nothing in biology

potential treatment for patients
potential treatment for patients with

Restoring Biological Harmony for Patients with Debilitating Disease Restoring